Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a leader in ...

The Dexcom G6 iCGM system determines blood glucose levels in patients 2 years of age and older. The Food and Drug Administration (FDA) has authorized the marketing of the Dexcom G6 integrated ...

DexCom, Inc.DXCM recently announced that the FDA has granted a de novo approval for the marketing of the new Dexcom G6 CGM monitoring system to check blood sugar levels in children and adults without ...

This morning the Dexcom G6 Pro Continuous Glucose Monitoring System got the greenlight from the FDA. The latest technology can gather real-time glucose data over a period of 10 days and has the ...

Dexcom has announced that the US Food and Drug Administration (FDA) has approved its G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients aged 2 ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

A literature search was carried out for this briefing in accordance with NICE's interim process and methods statement for the production of medtech innovation briefings. This briefing includes the ...

For those in the diabetes community who’ve dreamed about seeing their in-the-moment blood sugar readings and trend data right on their smartwatch or bike computer while exercising, Dexcom and Garmin ...

Life-changing CGM system indicated for persons age 2 years and older, now available for wear on back of the upper arm, giving patients more options EDINBURGH, Scotland, June 9, 2020 /PRNewswire/ -- ...

The U.S. Food and Drug Administration has announced a recall of specific Dexcom (NASDAQ:DXCM) glucose monitoring devices, including the G6, G7, ONE, and ONE+ models. The recall is due to a potential ...